Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.

Despite recent advances, non-small-cell lung cancer remains a devastating disease and carries a grim prognosis. Major contributing factors include difficulties in diagnosing the disease early in its course during the asymptomatic stage and the poor understanding of the biology underlying disease progression. Liquid biopsies, noninvasive blood tests that detect circulating biomarkers such as circulating tumor cells and tumor-derived nucleic acid fragments, are in a rapidly evolving field of research that could provide answers to both of these unmet needs. Herein, we review the relevant data concerning the diagnostic, predictive, and prognostic significance of 3 distinct but potentially complementary circulating biomarkers in non-small-cell lung cancer: circulating tumor cells, cell-free DNA, and microRNAs.

[1]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[2]  Patrick Maisonneuve,et al.  A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer , 2011, EMBO molecular medicine.

[3]  Xiaohong Wu,et al.  Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. , 2010, Lung cancer.

[4]  Walter Weder,et al.  Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Pantel,et al.  Circulating epithelial cells in patients with benign colon diseases. , 2012, Clinical chemistry.

[6]  D. Planchard,et al.  Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Slomka,et al.  MicroRNAs-Role in Lung Cancer , 2014, Disease markers.

[8]  Hong Peng,et al.  Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. , 2010, Lung cancer.

[9]  D. Tang,et al.  microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation , 2013, Medical Oncology.

[10]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[12]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[13]  Matteo Brunelli,et al.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.

[14]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[15]  C. Schumann,et al.  Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells , 2015, Clinical Cancer Research.

[16]  Quan Zhang,et al.  Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. , 2013, The Journal of molecular diagnostics : JMD.

[17]  E. Gallardo,et al.  Prognostic implications of miR‐16 expression levels in resected non‐small‐cell lung cancer , 2011, Journal of surgical oncology.

[18]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[20]  M. Delgado-Rodríguez,et al.  Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection , 2016, PloS one.

[21]  R. Murthy,et al.  Use of research biopsies in clinical trials: are risks and benefits adequately discussed? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Caroline Dive,et al.  Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.

[23]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yukiko Nakamura,et al.  Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[26]  Jaafar Bennouna,et al.  Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. , 2013, Lung cancer.

[27]  P. Holdgaard,et al.  The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC , 2013, British Journal of Cancer.

[28]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[29]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[30]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[31]  N. Tsubota,et al.  Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer , 2009, Clinical Cancer Research.

[32]  Y. Shu,et al.  MiRNA-21 , 2012, Cancer biology & therapy.

[33]  S. Horswell,et al.  Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Jie Luo,et al.  Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis , 2014, Scientific Reports.

[35]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[37]  Yingdong Zhao,et al.  MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.

[38]  Gideon Rechavi,et al.  Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  U. Anido,et al.  Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment , 2014, Cancers.

[40]  D. Planchard,et al.  High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Molina,et al.  Morphological analysis of circulating tumour cells in patients undergoing surgery for non‐small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method , 2012, Cytopathology : official journal of the British Society for Clinical Cytology.

[43]  Louise C. Showe,et al.  Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System , 2011, Clinical Cancer Research.

[44]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Marquette,et al.  ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Feng Jiang,et al.  Analysis of MicroRNAs in Sputum to Improve Computed Tomography for Lung Cancer Diagnosis , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[47]  A. Keller,et al.  MicroRNA expression changes after lung cancer resection , 2012, RNA biology.

[48]  Marius Ilie,et al.  “Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease , 2014, PloS one.

[49]  Yingyong Hou,et al.  Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. , 2012, American journal of respiratory and critical care medicine.

[50]  Ugo Pastorino,et al.  Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. , 2009, American journal of respiratory and critical care medicine.

[51]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[52]  M. Stroun,et al.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[53]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[54]  Y. Jeon,et al.  TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. , 2011, Lung cancer.

[55]  T. Mok,et al.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy , 2015, Clinical Cancer Research.

[56]  K. Pantel,et al.  A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells , 2016, International journal of cancer.

[57]  V. Adamo,et al.  Circulating miR‐22, miR‐24 and miR‐34a as Novel Predictive Biomarkers to Pemetrexed‐Based Chemotherapy in Advanced Non‐Small Cell Lung Cancer , 2013, Journal of cellular physiology.

[58]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[59]  F. André,et al.  Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? , 2014, Cancer treatment reviews.

[60]  C. Simone,et al.  Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results , 2015, Cancer.

[61]  Geoffrey R. Oxnard,et al.  Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients , 2015, Clinical Cancer Research.

[62]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[63]  Feng Jiang,et al.  Plasma microRNAs as potential biomarkers for non-small-cell lung cancer , 2010, Laboratory Investigation.

[64]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[65]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[66]  A. Marchetti,et al.  Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment , 2014, PloS one.

[67]  S. Kusumoto,et al.  Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. , 2012, Oncology research.

[68]  N. Girard,et al.  Comparisons of microRNA Patterns in Plasma before and after Tumor Removal Reveal New Biomarkers of Lung Squamous Cell Carcinoma , 2013, PloS one.

[69]  C. Bai,et al.  Early Detection of Lung Cancer in Serum by a Panel of MicroRNA Biomarkers. , 2015, Clinical lung cancer.

[70]  P. Validire,et al.  Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  K. Schütze,et al.  Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. , 2000, The American journal of pathology.

[72]  E. Vasile,et al.  Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer , 2014, Expert review of molecular diagnostics.

[73]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[75]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[76]  M. Paci,et al.  Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. , 2009, Lung cancer.

[77]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[78]  Jian-zhong Zhang,et al.  Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. , 2015, International journal of clinical and experimental pathology.

[79]  Feng Jiang,et al.  Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[80]  R. McCormack,et al.  Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[81]  G. Hampton,et al.  Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.

[82]  X. Xie,et al.  Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients , 2013, Proceedings of the National Academy of Sciences.

[83]  Tao Zhang,et al.  Prognostic Significance of Circulating Tumor Cells in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis , 2013, PloS one.

[84]  Feng Jiang,et al.  Quantification of Plasma miRNAs by Digital PCR for Cancer Diagnosis , 2013, Biomarker insights.

[85]  Caroline Dive,et al.  Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[86]  U. Pastorino,et al.  Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer , 2003 .

[87]  C. Paweletz,et al.  Realizing the potential of plasma genotyping in an age of genotype-directed therapies. , 2014, Journal of the National Cancer Institute.

[88]  K. Pantel,et al.  Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer , 2015, Front. Oncol..

[89]  J Carl Barrett,et al.  EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. , 2015, Lung cancer.

[90]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[91]  R. Catarino,et al.  Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients , 2012, PloS one.

[92]  A. Fiorelli,et al.  Circulating Tumor Cells in Diagnosing Lung Cancer: Clinical and Morphologic Analysis. , 2015, The Annals of thoracic surgery.

[93]  T. Jiang,et al.  Role of circulating-tumor DNA analysis in non-small cell lung cancer. , 2015, Lung cancer.

[94]  Surinder Kumar,et al.  Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer , 2010, European Respiratory Journal.

[95]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Á. Zaballos,et al.  Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival , 2010, European Respiratory Journal.

[97]  J. Lunceford,et al.  Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors , 2015, Journal of Immunotherapy for Cancer.

[98]  A. Paradiso,et al.  Molecular Profiling of Thin-Prep FNA Samples in Assisting Clinical Management of Non-Small-Cell Lung Cancer , 2013, Molecular Biotechnology.

[99]  T. Wurdinger,et al.  Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer , 2015, Oncotarget.

[100]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[101]  H. Wakelee,et al.  Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). , 2015 .

[102]  A. Marchetti,et al.  Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[103]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[104]  M. Ladanyi,et al.  Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.

[105]  J. Gomez-Codina,et al.  Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine , 2014, Clinical and Translational Oncology.

[106]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[107]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[108]  S. Nishizuka,et al.  Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel , 2016, PloS one.

[109]  Juan Zhao,et al.  Clinical use of microRNAs as potential non‐invasive biomarkers for detecting non‐small cell lung cancer: A meta‐analysis , 2015, Respirology.

[110]  Xiao-guang Liu,et al.  Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients , 2012, Medical Oncology.

[111]  T. Kohno,et al.  Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers , 2014, Modern Pathology.

[112]  T. Molina,et al.  Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non‐small‐cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method , 2011, International journal of cancer.

[113]  Zhang Wei,et al.  Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis , 2012, Journal of Cancer Research and Clinical Oncology.

[114]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[115]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[116]  D. Mavroudis,et al.  Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.